Pirfenidone experience in mild-to-moderate Idiopathic Pulmonary Fibrosis in a General Hospital.

Javier Martínez-Moreno


This article present the experience and outcomes of patients treated with pirfenidone.

FVC and DLCO parameters during 12 months were collected in patients treated with pirfenidone.

Eight of the ten patients continued treatment until month 12. 7 patients presented at 12 months an adequate response treatment, 1 patient did not achieve therapeutic targets established (improvement or stability).

At week 52, our patients had a mean change in FVC(%) of -2.38±6.93% versus -5.2% of clinical trials and -8.3% on placebo. Higher incidence of adverse effects were observed in absolute terms, than clinical trials.

Our results show that pirfenidone is a well tolerated drug, whose toxicity can be controlled by dose adjustment, and it is effective in mild-moderate IPF within one year. In this context, no proven effectiveness and safety medium / long term and the high economic impact, it is necessary to identify those patients who may derive greater clinical benefit.

Palabras clave

Pirfenidone; Idiopathic pulmonary fibrosis; forced vital capacity; Safety

Texto completo:

PDF (English)

Copyright (c) 2016 Real Academia Nacional de Farmacia